The goal of the MSK-Cornell Center for Translation of Cancer Nanomedicine is to advance, translate, and disseminate a suite of ultrasmall, multimodality, core-shell silica nanoparticles.
The center’s activities focus on the development and future implementation of newer classes of clinically promising particle imaging platforms for:
Impacting surgical care
Optical particle probes are being developed to more reliably detect, stage, and treat disease in the operating room.
Markedly improving drug delivery and treatment efficacy
Ultrasmall particles are being designed to carry small molecular drugs or radiotherapy labels. These can target and treat molecular-genetic alterations that may lead to tumor progression, as well as enhance tumor cell kill.
Novel diagnostic and therapeutic nanotechnologies that can enable earlier and more specific detection of cancer, as well as enhance treatment response, are critically needed to improve patient outcomes.
— Ulrich Wiesner, PhD
The translational research efforts of the MC²TCN multi-disciplinary team enable discovery and tool development toward the application of nanotechnology to clinical oncology. Learn about these projects here.
Learn about the research priorities of the MSK-Cornell Center for Translation of Cancer Nanomedicine and apply for project funding.
View a list of publications arising from research funded through MC²TCN.
Meet the MSK-Cornell Center for Translation of Cancer Nanomedicine principal investigators/co-directors, executive committee, external advisory board, faculty, lab members, and staff.
Our Center partners with the Nanobiotechnology Center at Cornell University which combines world-class nanofabrication and analysis tools with experience in interdisciplinary research.
Contact the MSK-Cornell Center for Translation of Cancer Nanomedicine team with questions or comments.